公开(公告)号：US20240308995A1

公开(公告)日：2024-09-19

申请号：US18673619

申请日：2024-05-24

Applicant: BIOGEN MA INC.

Inventor： Nathan Genung ,  Kevin M. Guckian ,  Jeffrey Vessels ,  Lei Zhang ,  Ryan Gianatassio ,  Edward Yin Shiang Lin ,  Zhili Xin

IPC: C07D417/14 ,  A61P25/28 ,  C07D417/06

CPC classification number: C07D417/14 ,  A61P25/28 ,  C07D417/06

Abstract: Described herein are compounds represented by formulas (IA) or (IB)




or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.

公开(公告)号：US11427561B2

公开(公告)日：2022-08-30

申请号：US16071200

申请日：2017-01-18

Applicant: BIOGEN MA INC.

Inventor： Timothy Chan ,  Kevin M. Guckian ,  Tracy Jenkins ,  Jermaine Thomas ,  Jeffrey Vessels ,  Gnanasambandam Kumaravel ,  Robert Meissner ,  Joseph P. Lyssikatos ,  Brian Lucas ,  Irina Leaf ,  Jeremy Duffield ,  Nathan Genung

IPC: C07D401/14 ,  A61K45/06

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.

公开(公告)号：US12275728B2

公开(公告)日：2025-04-15

申请号：US18673619

申请日：2024-05-24

Applicant: BIOGEN MA INC.

Inventor： Nathan Genung ,  Kevin M. Guckian ,  Jeffrey Vessels ,  Lei Zhang ,  Ryan Gianatassio ,  Edward Yin Shiang Lin ,  Zhili Xin

IPC: C07D417/14 ,  A61P25/28 ,  C07D417/06

Abstract: Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.

公开(公告)号：US11459324B2

公开(公告)日：2022-10-04

申请号：US16978550

申请日：2019-03-13

Applicant: BIOGEN MA INC.

Inventor： Nathan Genung ,  Kevin M. Guckian ,  Jeffrey Vessels ,  Lei Zhang ,  Ryan Gianatassio ,  Edward Yin Shiang Lin ,  Zhili Xin

IPC: C07D417/14 ,  C07D417/06 ,  C07D471/04

Abstract: Described herein are compounds represented by formula (I″) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y1, Y2, R3 and R4 are defined herein.

公开(公告)号：US20210188809A1

公开(公告)日：2021-06-24

申请号：US16071200

申请日：2017-01-18

Applicant: BIOGEN MA INC.

Inventor： Timothy Chan ,  Kevin Guckian ,  Tracy Jenkins ,  Jermaine Thomas ,  Jeffrey Vessels ,  Gnanasambandam Kumaravel ,  Robert Meissner ,  Joseph P. Lyssikatos ,  Brian Lucas ,  Irina Leaf ,  Jeremy Duffield ,  Nathan Genung

IPC: C07D401/14 ,  A61K45/06

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.

公开(公告)号：US12180205B2

公开(公告)日：2024-12-31

申请号：US17276502

申请日：2019-09-18

Applicant: BIOGEN MA INC.

Inventor： Nathan Genung ,  Kevin M. Guckian ,  Jeffrey Vessels ,  Lei Zhang ,  Ryan Gianatassio ,  Edward Yin Shiang Lin ,  Zhili Xin

IPC: C07D417/14 ,  A61P25/28 ,  C07D417/06

Abstract: Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.

公开(公告)号：US20230117898A1

公开(公告)日：2023-04-20

申请号：US17894461

申请日：2022-08-24

Applicant: BIOGEN MA INC.

Inventor： Nathan Genung ,  Kevin M. Guckian ,  Jeffrey Vessels ,  Lei Zhang ,  Ryan Gianatassio ,  Edward Yin Shiang Lin ,  Zhili Xin

IPC: C07D417/14 ,  C07D417/06 ,  C07D471/04

Abstract: Described herein are compounds represented by formula (I″) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y, Y2, R3 and R4 are defined herein.

公开(公告)号：US20220106305A1

公开(公告)日：2022-04-07

申请号：US17428323

申请日：2020-02-03

Applicant: BIOGEN MA INC.

Inventor： Nathan Genung ,  Kevin M. Guckian ,  Jeffrey Vessels ,  Lei Zhang ,  Ryan Gianatassio ,  Edward Yin Shiang Lin ,  Zhili Xin

IPC: C07D417/14 ,  C07D495/04 ,  C07D487/04 ,  C07D491/048 ,  C07D471/04

Abstract: Described herein are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, n and p are as defined herein.

公开(公告)号：US20220017506A1

公开(公告)日：2022-01-20

申请号：US17311232

申请日：2019-12-04

Applicant: BIOGEN MA INC.

Inventor： Nathan Genung ,  Kevin M. Guckian ,  Jeffrey Vessels ,  Lei Zhang ,  Ryan Gianatassio ,  Edward Yin Shiang Lin ,  Zhili Xin

IPC: C07D417/12 ,  C07D417/14

Abstract: Described herein are compounds represented by formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, m, n, and p are as defined herein.

公开(公告)号：US20240360157A1

公开(公告)日：2024-10-31

申请号：US18260275

申请日：2022-01-06

Applicant: BIOGEN MA INC.

Inventor： Nathan Genung ,  Tamara Halkina Levin

IPC: C07D519/00 ,  A61K31/5025 ,  A61K31/53

CPC classification number: C07D519/00 ,  A61K31/5025 ,  A61K31/53

Abstract: This disclosure relates to compounds of formula (I′), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the application. The compounds of the present disclosure are capable of inhibiting the activity of tyrosine kinase 2 (TYK2). The disclosure further provides methods of preparing the compounds of the disclosure, and methods for their therapeutic use.